News | December 14, 2021
Baxter acquires Hillrom for US $ 15 billion
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
The proposed week-long event will comprise specific themes - International engagements, market access and incubation support, funding support to startups etc. and will cover the different areas of the innovation lifecycle
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Sputnik M is a new member of the Sputnik vaccines family
Subscribe To Our Newsletter & Stay Updated
